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Objective: Transplant arteriosclerosis is the major determinant for long-term 
survival of cardiac transplants. Estradiol treatment inhibits transplant arte- 
riosclerosis. The objective of this study is to determine, in the absence of 
immunosuppression, thetemporal effect of estradiol treatment on the expres- 
sion of insulin-like growth factor, platelet-derived growth factor, basic fibro- 
blast growth factor, and major histocompatibility complex class II antigen in 
rat aortic allografts.Methods: Orthotopic abdominal aortic allograft ransplan- 
tation was performed in male rats with Brown-Norway rats used as donors and 
Lewis rats as recipients. The recipients (n = 50) were treated with estradio120 
/tg/kg per day or placebo by osmotic minipump for 2 days before the operation 
and until they were put to death on postoperative days 1, 3, 7, 14, or 21. The 
allografts were harvested and insulin-like growth factor, platelet-derived 
growth factor, basic fibroblast growth factor, and major histocompatibility 
complex class II antigen expression were determined by immunohistochemical 
staining. Myointimal thickening was measured by morphometric analysis. 
Results: In the placebo-treated group, insulin-like growth factor protein pro- 
gressively increased in all three layers of the allograft, whereas platelet-derived 
growth factor protein peaked at day 3 and basic fibroblast growth factor 
protein increased only moderately. Estradiol treatment inhibited the continu- 
ous increase in insulin-like growth factor expression, the peak in platelet- 
derived growth factor expression at day 3, the moderate basic fibroblast growth 
factor increase at day 21, and major histocompatibility complex class II 
antigen expression in all three layers of the allograft at day 21. Intimal 
thickening of allografts from estradiol-treated recipients was twofold to 
threefold less than that of the placebo-treated recipients at day 21. Conclusion: 
The development of transplant arteriosclerosis is associated with an early 
alloimmune response involving sustained increase in insulin-like growth factor 
expression. Estradiol treatment ofthe recipient inhibits transplant arterioscle- 
rosis and suppresses insulin-like growth factor and major histocompatibility 
complex class II antigen expression but not platelet-derived growth factor or 
basic fibroblast growth factor in all three layers of the allograft during the early 
posttransplantation alloimmune rejection phase. (J Thorac Cardiovasc Surg 
1997;114:803-10) 
A ccelerated coronary arteriosclerosis in recipients of cardiac allografts is still the major cause of 
death or retransplantation after the first 3 months. 
The pathogenesis may relate to an immune inflam- 
matory reaction in the vascular wall involving 
transendothelial nd adventitial inflammatory cell 
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invasion accompanied by release of chemotactic and 
mitogenic cytokines and growth factors. These 
events promote proliferation and migration of 
smooth muscle cells into the subendothelial layer. 
Insulin-like growth factor (IGF-I) is increasingly 
recognized to stimulate lymphocyte production and 
function. 1Recently, we reported that IGF-I admin- 
istered directly to the graft accelerates transplant 
arteriosclerosis 2 and that coadministration f estra- 
diol abrogates this effect. 3
The protective role of estrogen hormone replace- 
ment therapy in cardiovascular disease in women is 
documented. 4 Recently we 5 found that estradiol 
treatment of the recipient inhibits allograft coronary 
myointimal hyperplasia nd abolishes both IGF-I 
protein expression in the vascular wall and IGF-I 
mitogenic effects on allograft vessels ex vivo, thus 
further establishing a role for IGF-I in transplant 
arteriosclerosis. 
Here, we describe the temporal relationship be- 
tween the expression of growth factors (IGF-I, 
platelet-derived growth factor [PDGF-BB], and ba- 
sic fibroblast growth factor [bFGF]) and myointimal 
hyperplasia fter transplantation. We also show that 
estradiol, independently of cyclosporine A (INN: 
ciclosporin), inhibits growth factor, major histocom- 
patibility complex (MHC) class II expression, and 
myointimal thickening. The aortic allograft model 
was used because immunosuppression is not re- 
quired for grafts to serve as a functional conduit, 
thus avoiding a possible effect of cyclosporine A on 
transcriptional ctivity of the estradiol receptor li- 
gand complex owing to the reported association of 
cyclophilin with the inactive estradiol receptor. 6 
Materials and methods 
Animals. Male rats (250 gin) were purchased from 
Harlan Sprague Dawley (Indianapolis, Ind.) and housed 
in a facility approved by the American Association for 
Accreditation of Laboratory Animal Care that was main- 
tained at 20 ° C with scheduled 12-hour light cycles. The 
animals were fed rat chow diet ad libitum and acclima- 
tized at least for 1 week before use. All animals received 
humane care in compliance with the "Principles of Labo- 
ratory Animal Care" formulated by the National Society 
for Medical Research and the "Guide for the Care and 
Use of Laboratory Animals" prepared by the National 
Institute of Laboratory Animal Resources and published 
by the National Institutes of Health (NIH Publication No. 
85-23, revised 1985). 
Transplantation procedure. Orthotopic transplanta- 
tion of abdominal aortic allografts was performed with 
Brown-Norway rats used as donors and Lewis rats as 
recipients as previously described) In short, donors and 
recipients were anesthetized with ketamine, 80 mg/kg, and 
xylazine, 10 mg/kg. The donor abdominal aorta was 
isolated and resected after intravenous injection of hepa- 
rin, 200 units/kg. The recipient aorta was transected 
between two microvascular clamps (Micro Vessel Clip, 
Biomedical Research Instruments, Rockville, Md.), and 
the donor aorta was transplanted end to end with inter- 
mittent 10-0 nylon sutures (Accurate Corp., Westbury, 
N.Y.). The anastomosis was performed with the aid of a 
surgical microscope (Olympus Corp., Lake Success, N.Y.). 
Experimental groups. The recipients were randomly 
assigned to two groups: The group treated with estradiol- 
17/3 (n = 25) received a 20/xg/kg per day subcutaneous 
dose of estradiol cypionate (Depo-Estradiol, The Upjohn 
Company, Kalamazoo, Mich.) continuously by an osmotic 
minipump (Alza Corp., Palo Alto, Calif.) from 2 days 
before transplantation u til the animals were put to death. 
The placebo-treated group (n = 25) received an equal 
volume of placebo. The animals were put to death on 
posttransplantation days 1 (n = 6), 3 (n = 10), 7 (n = 12), 
14 (n = 12), or 21 (n = 10), at which time blood was drawn 
for determination f serum estradiol levels. 
Preparation of the aortic allograft. The recipients were 
put to death under deep anesthesia after heparin admin- 
istration. The aortic allografts were isolated and pressure- 
perfused at 80 mm Hg for 30 minutes with saline solution 
followed by formalin tissue fixative (Histochoice, Amresco 
Inc., Solon, Ohio). The grafts were cut horizontally into 
three segments, which were embedded in paraffin. Sec- 
tions of 6 /xm thickness were cut from each block for 
immunohistochemistry or stained with either hematoxy- 
lin-eosin or an elastin stain for histologic and morphomet- 
ric evaluation, respectively. 
Immunohistochemistry. The antibodies mentioned be- 
low were used as primary antibodies; their dilution ratio 
or concentration is given in parentheses. The monoclonal 
antibody for IGF-I (1:10,000) (10 /xg/ml) was kindly 
provided by Dr. P. Delafontaine at Emory University 
(Atlanta, Ga.). The monoclonal antibodies for platelet- 
derived growth factor-BB (PDGF-B) (1:300) and basic 
fibroblast growth factor (bFGF) type A (1:300) were 
purchased from Upstate Biotechnology Inc. (UBI, Lake 
Placid, N.Y.). MHC class II antigen expression was deter- 
mined at day 21 by using the OX6 monoclonal ntibody 
(Harlan Sera-lab Ltd., Sussex, United Kingdom) at 1:1000 
dilution. The immunohistochemistry staining was per- 
formed at room temperature with the use of the His- 
tostain SP Kit (Zymed, Inc., South San Francisco, Calif.) 
according to the protocol of the manufacturer. After 
dewaxing with xylene and rehydration with ethanol, the 
sections were placed in 3% hydrogen peroxide/100% 
methanol (Sigma Chemical Co., St. Louis, Mo.) for 20 
minutes, washed with phosphate-buffered saline solution 
(Biofluids Inc., Rockville, Md.) three times for 2 minutes, 
and then incubated in serum-blocking solution for 1 hour. 
The primary antibody was applied for 2 hours, washed 
with phosphate-buffered saline solution, and then incu- 
bated with biotin-labeled secondary antibody for 1 hour 
(Sigma). Thereafter, a streptavidin-peroxidase reaction 
system was applied, and hematoxylin (Sigma) was added 
for counterstaining. 
Grading of the immunohistoehemical staining. The 
intensity of the immunohistochemical st ining in intima, 
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Fig. 1. Posttransplantation IGF-I expression in rat aortic allografts from recipients treated with either 
estradiol-17/3 orplacebo. The expression of IGF-I is determined by grading (on a scale of 0 to 3) the degree 
of immunohistochemistry staining in intima (A), media (B), and adventitia (C). Three histologic ross 
sections from each allograft on day 1. 3, 7, 14, and 21 after transplantation were used. The data are 
expressed as mean _+ standard error of the mean. Estradiol-17/3 vs. placebo: A, day 7,p = 0.04; day 14,p = 
0.0008; day 21, p = 0.0003. B, day 3, p = 0.2; day 7, p = 0.09; day 14, p = 0.003; day 21, p = 0.01. C, day 
3, p = 0.3; day 7, p = 0.03; day 14, p = 0.003; day 21, p = 0102. 
media, and adventitia was graded by a scoring system 
from 0 to 3: no staining = 0; weak staining, showing a 
couple of patchy stained loci = 1; patchy staining in less 
than 50% of the area ~- 2; and more than 50% of the 
area strongly stained = 3. Three cross sections from 
each allograft were graded and the scores were aver- 
aged. This was done for all time points in both the 
estradioi and placebo treatment groups. The scoring 
was performed independently by two investigators 
blinded to the treatment groups. 
Morphometric analysis. The degree of intimal thicken- 
ing was determined by computed morphometry (The Mor- 
phometer, Woods Hole Educational Associates, Woods 
Hole, Mass.). Three horizontal sections from each allograft 
were examined. The intimal thickness was expressed as the 
area of myointima over the total Vessel area × 100% as 
previously described. 7 All measurements were done inde- 
pendently by two investigators blinded to treatment groups. 
Serum estradiol. Blood samples were obtained when 
the animals were put to death. The samples were centri- 
fuged and the serum was stored at -20 ° C: Estradiol-17/3 
was measured by radioimmunoassay (Diagnostic Products 
Corp., Los Angeles, Calif.). 
Statistical analysis. The data are expressed as means +_ 
standard error of the mean. Differences among the groups 
were compared by a two-way factorial analysis of variance 
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Table I. Posttransplantation PDGF-BB expression in rat aortic allografis from recipients treated with either 
estradiol-1713 orplacebo 
Intima Media Adventitia 
P P P 
Day Placebo Estradiol-17[3 Value Placebo Estradiol-17[3 Value Placebo Estradiol-17[3 Value 
1 0 0 0 0 0 0 
3 0 0 0.22 ± 0.10 0 0.2 0.50 -+ 0.11 0.17 ± 0.10 0.03 
7 0.17 + 0.08 0.10 -+ 0.10 0.3 0.14 ± 0.08 0.10 -+ 0.08 0.2 0.38 ± 0.10 0.17 -+ 0.09 0.9 
14 0.15 --- 0.08 0.10 ± 0.07 0.6 0.10 ± 0.06 0.10 ± 0.05 0.7 0.42 -+ 0.15 0.28 -+ 0.09 0.4 
21 0.27 --- 0.10 0.23 ± 0.10 0.7 0.10 ± 0.06 0.12 ± 0.06 0.9 0.33 -+ 0.11 0.25 -+ 0.11 0.6 
The expression of PDGF-BB was determined by grading on a scale of 0 to 3 the degree of immunohistochemistry taining in intima, media, and adventitia. 
Three histologic ross sections from each allograft on days 1, 3, 7, 14, and 21 after transplantation were used. The data are expressed as means -+ standard 
error of the mean. 
followed by multiple comparison analysis. When the vari- 
ances between the groups were found not to differ by, the 
F-test, Fisher's test was used for the multiple comparison 
analysis. The differences were considered statistically sig= 
nificant at p < 0.05. 
Results 
Expression of IGF-I in the aortic allograft 
Intima. IGF-i expression was present in both the 
placebo- and estradiol-1713-treated groups from 
days 7 and 14, respectively. Significantly less IGF-I 
protein was present at day 14 in the estradiol-1713- 
treated group than in the placebo-treated group 
(0.07 _+ 0.04 vs 0.72 + 0.20, p = 0.0008). This 
significant difference in IGF-I expression was main- 
tained at day 21 (0.10 _+ 0.08 vs 0.68 +_ 0.17, placebo- 
and estradiol-treated groups, respectively, p = 
0.0003) (Fig, 1, A). 
Media. The expression of IGF-I in the ailograft 
from the estradiol-17/3-treated group was signifi- 
cantly less than in the allograft from the placebo- 
treated group both at day 14 (0.11 _+ 0.07 vs 0.67 _+ 
0.12,p = 0.003) and at day21 (0.17 _+ 0.12 vs 0.63 _+ 
0.20, p = 0.01 ) (Fig. 1, B). 
Adventitia. IGF-I expression in the allografts 
from the placebo-treated group increased continu- 
ously from days 3 to 21, whereas IGF-I expression in 
the allografts from the estradiol-treated group was 
significantly less at day 7 (0.54 _+ 0.10 vs 0.38 -+ 0.08, 
p = 0.03), day 14 (0.78 _+ 0.12 vs 0.34 _+ 0.09, p = 
0.003), and day 21 (1.0 _+ 0.09 vs 0.67 _+ 0.09, p = 
0.02) (Fig. 1, C). 
Expression of PDGF-BB. In the placebo group, 
PDGF-BB expression peaked at day 3 in the adventitia 
and medial ayers whereas the expression continuously 
increased in the intima. In the estradiol-17[3-treated 
group, PDGF-BB expression was present from day 7 
in the intima and media and peaked at day 14 in the 
adventitia. At day 3, significantly less PDGF-BB ex- 
pression was seen in the adventitia of allografts from 
the estradiol-1713-treated group compared with allo- 
grafts from the placebo-treated group (0.17 _+ 0.10 vs 
0.50 _+ 0.11, p = 0.03) (Table I). No significant 
differences were observed at any other time point. 
Immunostaining for PDGF-BB in the allografts from 
both the placebo- and estradiol-1713-treated groups is 
shown in Table I. 
Expression ofbFGF. In the placebo group, bFGF 
expression was seen at day 3 in the media and 
adventitia and at day 7 in the intima, and the 
expression Continuously increased in all three layers. 
In the esn:adiol-1713-treated group, bFGF expres- 
sion continuously increased in the intima and adven- 
titia. At day 21, significantly less bFGF expression 
was seen in the media of allografts from the estra- 
diol-17[3-treated group compared with aliografts 
from the placebo-treated group (0.20 _+ 0.08 vs 
0.03 _+ 0.03, p = 0.002) (Table II). No significant 
differences were observed at any other time point. 
Immunostaining for bFGF in the allografts from 
both the placebo- and estradiol-1713-treated groups 
is shown in Table iI. 
Expression of MHC class II antigen 
Intima. At day 21 the MHC class II expression 
was up-regulated in the allografts from the placebo- 
treated group whereas the antigen was significantly 
depressed in the estradiol-1713-treated group 
(1.42 _+ 0.43 vs 0.14 + 0.07,p < 0.0001). 
Media. MHC class II antigen expression was 
present at day 21 in allografts from the placebo- 
treated group. In contrast, MHC class II antigen was 
absent in the allografts from the estradiol-1713- 
treated group (0.75 -+ 0.028 vs 0.00, p < 0.0001). 
Adventitia. The expression of MHC class II anti- 
gen in the allograft from the estradiol-1713-treated 
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Table II. Posttransplantation bFGF expression in rat aortic allografis from recipients treated with either 
estradiol-17/3 or placebo 
Intima Media Adventitia 
P P P 
Day Placebo Estradiol-17[3 Value Placebo EstradioL17[3 Value Placebo Estradiol-17[3 Value 
1 0 0 0 0 0 0 
3 0 0 0.16 -+ 0.06 0 0.1 0.14 -+ 0.06 0.11 _+ 0.06 0.7 
7 0.10 -+ 0.05 0.10 -+ 0.06 0.7 0.06 -+ 0.04 0 0.3 0.22 +- 0.06 0.19 -+ 0.06 0.8 
14 0.18 -+ 0.07 0.09 -+ 0.05 0.2 0.10 + 0.05 0.03 + 0.03 0.3 0.33 +- 0.07 0.30 -+ 0.06 0,8 
21 0.29 -+ 0.09 0.27 -+ 0.08 0.9 0.20 -+ 0.08 0.03 +- 0.03 0.002 0.48 + 0.12 0.33 +_ 0.10 0,1 
The expression of bFGF was determined bygrading on a scale of 0 to 3 the degree of immunohistochemistry taining in intima, media, and adventitia. Three 
histologic ross sections from each allograft on days 1, 3, 7, 14, and 21 after transplantation were used. The data are expressed as means -+ standard error 
of the mean. 
group was significantly ess than that of the placebo- 
treated group at day 21 (2.5 _+ 0.22 vs 0.25 +_ 0.10, 
p < 0.0001). 
Morphometric analysis of the aortic allograft. By 
light microscopy, intimal thickening was visible at 
day 7 and measurable atdays 14 and 21. The intimal 
thickening in the allografts from estradiol-17/3- 
treated recipients was twofold to threefold less than 
the intimal thickening in the a!lografts from place- 
bo-treated recipients at day 21 (9.5% _+ 2.0% vs 
24.9% + 3.6%,p = 0.001, Fig. 2). 
Serum estradiol. Serum estradiol-17/3 concentra- 
tion when the animals were put to death was ele- 
vated in the estradiol-17/3-treated animals to 
147.1 _+ 17.45 pg/ml compared with 8.42 _+ 2.14 
pg/ml in the placebo-treated control group (p = 
0.001). There was no significant difference in serum 
estradiol-17/3 values on days 1, 3, 7, 14, and 21 in the 
estradiol-treated animals. 
Discussion 
In the absence of immunosuppressi0n, treatment 
of recipients with estradiol-17/3 prevents the pro- 
gressive increase in allograft IGF-I expression after 
transplantation. There was little or no effect on 
PDGF-BB and bFGF expression, although myointi- 
ma! thickening was significantly inhibited. The allo- 
graft from the placebo group exhibited progressive 
expression of IGF-I from day 3 in adventitia nd 
peaked at day 14 in the intima and media, at which 
time allograft myointimal hyperplasia became mea- 
surable. This is in contrast o al!ografts from the 
estradiol-17/3-treated r cipients, wherein Signifi- 
cantly less IGF-I expression and myointimal hyper- 
plasia was observed, These data are in accord with 
our previous finding that rat aortic allografts ex- 
posed to IGF-I before grafting exhibited accelerated 
intimal thickening that was attenuated by estradiol- 
17/3 treatment of the recipients, z' 3 
Immunologic and nonimmunologic injury either 
directly or indirectly predisposes an allograft to 
proinflammatory c tokines leading to endothelial 
injury. 7Activated endothelial cells produce several 
growth factors that induce the transformation of
smooth muscle cells to the synthetic phenotype that 
replicates and migrates,  allograft arteriosclerosis 
progresses, and graft function deteriorates. Isch- 
emic. reperfusion, and immune injury are common 
to the allograft and up-regulate expression of IGF-I. 
bFGF. and PDGF-BB in both smooth muscle and 
endothelial cells. The normal vessel wall does not 
express any of these growth factors, and their ab- 
sence is also observed in our study 24 hours after 
transplantation (day 1). However, up-regulation of
the three growth factors is seen on day 3 after 
transplantation. Ischemia nd reperfusion injury is 
known to cause a peak in PDGF-BB and bFGF on 
day 3 and in IGF-I on days 4 to 5. 9-11 The progres- 
sive increase in IGF-I beyond ay 5 is induced by the 
alloimmune response. PDGF-BB does not exhibit a 
progressive increase. The continuous expression 
may be due to the initial ischemia nd reperfuslon 
injury or may be sustained by the alloimmune 
activity. There is a moderate but continuous in- 
crease in bFGF, unlike that after ischemic injury, 
suggesting that the alloimmune response is directly 
or indirectly involved in the expression of bFGF. 
IGF-I is a progressive growth factor that acts 
primarily on the G1 phase of the cell cycle to 
promote entry into the S phase, 12 whereas 
PDGF-BB is a competence factor unable to cause 
mitogenesis without IGF-I. In human coronary 
atherectomy specimens, IGF-I is more intensely 
expressed in the synthetic than in contractile smooth 
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Fig. 2. Intimal thickening of allograft aorta from the 
placebo-treated group (open bar) and from the estradiol- 
17/3-treated group (hatched bar) on day 21 after trans- 
plantation, Intimal thickening is expressed as a percentage 
of myointimal area over total vessel area (area within 
external elastic lamina). Three histologic cross sections 
from each allograft on days 1, 3, 7, 14, and 21 after 
transplantation were used. Estradiol-17/3 treatment signif- 
icantly (p = 0.001) reduced allograft ransplant arterio- 
sclerosis. The data are expressed as mean _+ standard 
error of the mean. 
muscle cells, suggesting that IGF-I expression is a 
function of the proliferative state of smooth muscle 
cells generating autocrine stimulation of growth. 13 
This mitogenic effect of IGF-I is abolished by co- 
incubation with a specific monoclonal anti-IGF-I 
antibody confirming the specific mitogenic role of 
IGF-I in smooth muscle cell proliferation. 5 This 
mitogenic effect also applies to the a!lograft in which 
a single local application of IGF-I accelerates trans- 
plant arteriosclerosis n vivo. 2 Recent studies by 
others support the notion that blocking IGF-I or 
IGF-I receptor will decrease smooth muscle cell 
proliferation. For example; an antisense IGF-I re- 
ceptor, oligonucleotide, abrogates the mitogenic ef- 
fects of both PDGF-BB and bFGF in smooth muscle 
cell cultures. ~4 Our present study demonstrates that 
estradiol treatment prevents IGF-I up-regulation, 
suggesting that attenuation of IGF-I expression is 
linked to inhibition of transplant arteriosclerosis. 
We have previously shown that estradiol treatment 
inhibits IGF-I expression in the allograft coronary 
artery 6 weeks after transplantation 5 in a rabbit 
transplant model in which the immunosuppressant 
cyclosporine A was given daily to avoid acute rejec- 
tion. The current data show that in the absence of 
cyclosporine A estradiol prevents the continuous 
and substantial up-regulation of IGF-I, supporting 
the hypothesis that IGF-I plays an important role in 
transplant arteriosclerosis. 
The role of IGF-I may relate to its effects on the 
immune system, z where it has a significant role in 
the maturation of lymphocytes in the bone marrow 
and assists their function in the periphery. In ro- 
dents, treatment with IGF-I can restore age-related 
thymic involution, increase lymphocyte number and 
activity, improve reduced antibody response to an 
antigen challenge, and accelerate lymphoid clonal 
expansion after immune injury. 15 In this present 
study, allografts from placebo-treated recipients ex- 
hibited progressive IGF-I expression in all three 
layers of vascular allograft with ongoing acute rejec- 
tion. Estradiol-17/3 inhibition of IGF-! expression 
may diminish both IGF-I-induced mitogenic effects 
and its stimulating effect on lymphocytes and their 
function. 
In this present study, significant reduction by 
estradiol-17/3 of transplant arteriosclerosis was asso- 
ciated with inhibition of inducible vascular MHC 
class II antigen expression. We 16 recently discovered 
that estradiol-17/3 abolishes MHC class [I antigen 
expression in the cardiac allograft in recipients 
immunosuppressed with cyclosporine A. Up-regula- 
tion of both constitutive and inducible MHC class II 
antigen expression plays a central role in immune 
activation associated with transplant arteriosclero- 
sis. The role of IGF-I in MHC class II antigen 
expression is not known at present. Interferon-7 
(INF-~/) is the known inducer of MHC class II 
expression i  allograft rejection 17 and thus may be a 
mediator of transplant arteriosclerosis. Interest- 
ingly, the INF-y gene is up-regulated by estradiol 
after binding of the estrogen receptor to the estro- 
gen receptor esponse lement, suggesting that sup- 
pression of MHC class II expression is not associ- 
ated with the IFN-3, gene but with the MHC class II 
gene or the class II transactivating gene. 18 
The lack of consistent suppression of PDGF-BB 
and bFGF expression in the estradiol-treated allo- 
graft, in the face of significant inhibition of trans- 
plant arteriosclerosis, uggests that these growth 
factors may be of less importance in transplant 
arteriosclerosis than in native artery atherosclerosis. 
Our results uggest that PDGF-BB is involved in the 
ischemia-reperfusion injury phase by inducing IGF-I 
receptor on lymphocytes, mooth muscle cells, and 
macrophages, thus augmenting the alloimmune-me- 
diated myointimal thickening in the early phase. 
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Autocr ine or paracr ine product ion of IGF - I  is be- 
l ieved to be necessary for PDGF-BB to exert mito- 
genic effects on smooth muscle cells and fibro- 
blasts. 19 This suggests that estradiol-17/3 inhibit ion 
of PDGF-BB expression on posttransplantat ion day 
3 in the media  is an indirect effect through suppres- 
sion of IGF - I  expression. 
In this p resent  study, estradiol-17/3 t reatment  of 
rec ip ients  d id not  affect the express ion of  bFGF 
on a l lograft  aor ta  in int ima and advent i t ia  and 
only inh ib i ted bFGF express ion on day 21 in the 
media.  Out  results ind icate that  estradiol-17/3 has 
no d i rect  inh ib i tory  effects on bFGF express ion in 
rat aort ic  al lografts.  IGF - I  is also repor ted  to 
increase bFGF- induced mitogenes is  and up-regu-  
late bFGF receptor  in vascular  smooth  muscle 
cells. 2° The tempora l  inhib i t ion of  bFGF expres- 
sion in the med ia  at day 21 in this study may be 
due to an indi rect  effect th rough estradiol-17/3 
suppress ion  of IGF - I  expression.  
Conclusion 
In the absence of immunosuppress ion,  estradiol  
t reatment  of recipients prevents a progressive in- 
crease in IGF - I  and MHC class I I  antigen expres- 
sion, but not PDGF-BB or bFGF expression in all 
three layers of the rat aortic allograft. The accom- 
panying inhibit ion of t ransplant arteriosclerosis 
lends further support  for the suggestion that IGF - I  
expression has a crucial role in the early phase of 
acute rejection. 
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Discussion 
Mr. Magdi Yacoub (London, England). Induction of 
class II MHC antigen expression and infiltration by mac- 
rophages are relatively late events. What do you think 
about the mechanism of the action of estradiol? Have you 
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looked at induction of nitric oxide synthase, for example, 
or some cytokines? 
Dr. Saito. MHC class expression is inducible in many 
MHC class II negative cells, such as smooth muscle cells 
and endothelial cells, by a variety of stimuli, particularly 
INF-7. Both constitutive and inducible gene expression is
controlled primarily by the recently identified class II 
transcription activated gene, CIITA, so we are speculating 
that estrogen is directly affecting these genes. 
Dr. Hikaru Matsuda (Osaka, Japan). Have you tested 
this experiment in the other matching model of the animals 
with a different combination of the MHC class II antigen? 
Second, we have shown that there are some triggers that 
occur during the early period after transplantation to
promote coronary atherosclerosis. Have you tried giving 
estradiol-17/3 only until 5 days or so and seeing what 
happens afterward? 
Dr. Saito. The combination of donor and recipient 
strains used here is very much allogenic, probably the 
strongest allogenic hronic rejection model. We did not 
use other combinations. 
We have shown that at 6 weeks after transplantation in 
the rabbit model, estradiol completely abolished the ex- 
pression of MHC class II antigen in all three areas of 
intima, media, and adventitia. We have not tried short- 
term treatment like 5 days. 
Dr. Charles A. Yankah (Berlin, Germany). Did you 
observe in your series whether there were some changes 
or inhibition of migration of the myofibroblasts onto 
the endothelial surfaces? Migration of myofibroblasts is 
an important mechanism for the induction of arterio- 
sclerosis. 
Dr. Saito. I understand that migration from the medial 
area to the intima and perhaps of myofibroblast from the 
adventitia is a very important mechanism for the devel- 
opment of intimal hyperplasia. We did not study migra- 
tion as such, but myointimal thickening was reduced by 
estradiol. 
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